In 1977, the world’s first effective treatment for a viral disease occurred at University Hospital. Richard Whitley, M.D., and Charles Alford developed vidarabine, the first drug to treat encephalitis caused by the herpes simplex virus. Their achievement opened the door to the whole field of antiviral therapy, and today antivirals are a vital part of the pharmacological arsenal, used to treat influenza, HIV and many other conditions.
Whitley, now a Distinguished Professor of infectious diseases, is still doing groundbreaking treatment research as principal investigator of a $37.5 million, five-year U19 grant from the National Institute of Allergy and Infectious Disease Centers of Excellence for Translational Research to study and develop treatment for high-priority emerging infections. That research helped develop the investigational drug remdesivir, which is being used to treat select infected patients in the United States and China who have been affected by COVID-19.
Read through more stories from the UAB Reporter to see how more investigators across UAB have mobilized their research interests to help us better understand and fight coronavirus.
Virologist Kevin Harrod, Ph.D., is the institution’s resident expert on SARS viruses. His lab is handling biological validation for innovative drug-repurposing studies supported by the School of Medicine’s Urgent COVID-19 research fund.
Read more
Microbiologists Troy Randall and Frances Lund are building key proteins from several coronaviruses to study antibody cross-reactivity and other crucial questions in this project supported through UAB’s urgent COVID-19 research fund.
Read more
In this project supported through UAB’s urgent COVID-19 research fund, Professor Randall Davis aims to identify antibodies that block SARS-CoV-2 from entering human cells — information that could guide convalescent plasma therapy and more.
Read more
In this project supported through UAB’s urgent COVID-19 research fund, Assistant Professor Benjamin Larimer, Ph.D., adapts his lab’s work on phage display — normally used to identify new cancer treatments — to overcome limitations of antibody and vaccine testing.
Read more
Trial to rapidly identify and treat the immune overreaction that may be behind some cases of severe COVID-19 is made possible through UAB Medicine’s Urgent COVID-19 Clinical Research and Laboratory Research Fund.
Read more